观点聚焦 Investment Focus
disclaimer)
泰格医药 Hangzhou Tigermed Consulting (300347 CH)
点评： 24Q2 业绩环比恢复趋势明显，针对性业务策略推动长期增长
Review Obvious Recovery Trend of 24Q2  Targeted Business Strategies to Promote Long-term Growth
维持优于大市Maintain OUTPERFORM
来源 盟浪 Reproduced by permission no further distribution
Rmb3111bn  US436bn
日交易额 (3 个月均值)
US6150mn
1 年股价最高最低值
Rmb7175-Rmb3785
注：现价Rmb4868 为2024 年08 月28 日收盘价
资料来源： Factset
Revenue (-)
Net profit (-)
Diluted EPS (Rmb)
资料来源：公司信息 HTI
(Please see APPENDIX 1 for English summary)
2024H1：营业收入3358 亿元（-95%），毛利率为397%
（-022pct），归母净利润为493 亿元（-645%），扣非归母净利
润640 亿元（-193%）。
2024Q2 ：营业收入1698 亿元（-109% ），毛利率为415%
（135pct），归母净利润为258 亿元（-686%），扣非归母净利
润337 亿元（-182%），环比增长113%。
国内创新药临床运营迎来好转，临床项目数稳定增长。2024H1，
临床试验技术服务板块收入1637 亿元，同比下降2217%，毛利率
为3836%（-138pct）。板块收入同比下降主要原因：1）2023H1
有部分特定疫苗项目相关收入；2）国内创新药临床运营业务收入
同比下滑。我们认为，国内创新药临床运营业务在2024 年第二季
度较第一季度有所好转，且好转趋势有望延续。截至2024 年6 月
30 日，公司正在进行的项目800 个，其中临床期340 个，期
147 个，期192 个，期30 个，其他项目91 个。公司有537 个
药物临床研究项目在境内开展，较2023 年同期增加34 个，263 个
项目在境外开展，其中有208 个项目在境外（包括韩国、澳大利亚
及美国）进行单一区域临床试验；有55 个项目进行多区域临床试
临床试验相关及实验室服务营收稳定增长。2024H1，板块营业收
入1659 亿元，同比增长584%，毛利率为3988%（019pct）。
2024H1，全球数统客户数量由2023 年同期的296 家增至超过330
家；有824 个正在进行的数统项目，其中489 个项目由国内团队实
施，335 个项目由海外团队实施。SMO 业务公司完成165 个项目，
新签订单同比增长34%，正在进行的SMO 项目由上年末的1952 个
增至2110 个；公司独立影像评估团队新增客户超过10 家。公司建
立临床运营策略委员会，汇集相关资源和专家，强化临床策略方面
的能力，并有效提升临床项目竞标成功率以促进订单转化。公司成
立针对MNC 跨国药企的解决方案部，制定面向MNC 的客户开发和
市场拓展策略，促进长期战略合作并提供一站式解决方案。
服务领域覆盖全产业链，各团队携手助力产品上市。公司上半年为
15 个获批的中国1 类新药提供了服务，累计国际多中心临床试验
(MRCT)项目经验133 个。
泰格医药 (300347 CH)
报告期内，医疗器械团队助力2 款创新器械产品成功上市（支气管导航操作控制系统、二尖瓣夹系统）；注册团队助
力2 个产品在中国注册上市获批，29 项INDMRCT 临床试验申请在多个国家获得临床批件，新增美国FDAIND 项目21
个，其中19 项已获FDA 受理；数统部门助力11 款新药在中国、美国和日本获批；现场管理团队为9 个中国已获批1
类新药提供了SMO 现场管理服务；独立影像评估团队成功助力3 个新药获批上市、4 个项目递交申报。
市场份额保持领先地位，外延收购加强全球布局。2023 年，泰格医药以 128%的市场份额保持中国临床外包服务市场
的领先地位，是2023 年唯一进入全球前十的中国临床外包服务提供商，全球市场份额 14%。2024H1，公司收购日本
CRO 公司 Medical Edge，进一步拓展在日本及亚太的数统和数据管理服务。公司全球员工数量 9348 人，包括海外员工
1722 名，覆盖全球 37 个国家，截至2024 年上半年，累计国际多中心临床试验(MRCT)项目经验 133 个。公司持续对以
美国、澳大利亚和欧洲为代表的海外市场进行投入，建立独立的海外业务能力和品牌，在稳固国内客户出海项目的基
础上，拓展国外客户的本土项目。
考虑到国内生物医药投融资环境仍在逐渐恢复阶段，生物医药企业客户研发支出增速放缓，我们预计泰格医药2024-
2026 年收入分别为7178、8388、9913 亿元（原预测为8277 9690 11467 亿元），同比增速-28%、169%、182%；
归母净利润分别为1297、2058、2298 亿元（原预测为2281 2636 3088 亿元），同比增速-359%、586%、117%，扣
非归母净利润1445、1758、1948 亿元，同比增速-22%、217%、108%。我们给予泰格医药 2024 年扣非归母净利润
35 倍 PE（原为30x），对应公司合理每股价格 5846 元，维持优大于市评级。
行业竞争加剧；药企研发需求下降；业务扩展不及预期；投资收益受市场波动影响。
泰格医药 (300347 CH)
泰格医药 (300347 CH)
泰格医药 (300347 CH)
泰格医药 (300347 CH)
APPENDIX 1
2024H1 results sales of 3358 billion yuan (-95%) gross margin of 397% (-022 pct) net profit attributable to shareholders of
493 million yuan (-645%) net Profit attributable to shareholders excluding non-recurring gains and losses 640 million yuan (-
258 million yuan (-686%) net Profit attributable to shareholders excluding non-recurring gains and losses 337 million yuan
(-182%)  up 113% QoQ
Clinical operation of domestic innovative drugs has seen an improvement and the number of clinical projects is growing
steadily2024H1 the revenue of clinical trial technical service segment was RMB 1637 billion down 2217% year-on-year with
a gross profit margin of 3836% (-138 pct) The main reasons for the year-on-year decline in segment revenue are 1) some
specific vaccine program-related revenue in 2023H1 and 2) year-on-year decline in revenue from domestic innovative drug
clinical operation business We believe that the domestic innovative drug clinical operation business improved in the second
The Company has 537 drug clinical research projects conducted in China an increase of 34 projects from the same period in
2023 and 263 projects conducted outside China of which 208 projects are conducting single-region clinical trials outside China
(including South Korea Australia and the United States) and 55 projects are conducting multi-region clinical trials
Clinical trial-related and laboratory services revenue grew steadilyIn 2024H1 segment revenue was RMB1659 billion up 584%
year-on-year with a gross margin of 3988% (019 pct)In 2024H1 the number of global counting system clients increased to
more than 330 up from 296 during the same period of 2023 there were 824 ongoing counting system projects with 489 of
these projects were carried out by domestic teams and 335 projects were carried out by overseas teamsSMO businessThe
increased to 2110 from 1952 at the end of the previous year the Companys independent imaging evaluation team added more
than 10 new clients The Company established the Clinical Operations Strategy Committee to pool relevant resources and experts
strengthen the capability in clinical strategy and effectively enhance the success rate of clinical project bidding to promote order
strategies for MNCs promoted long-term strategic cooperation and provided one-stop solutions
The service area covers the whole industry chain and the teams work together to help the products go to market In the first
international multi-center clinical trial (MRCT) projects During the reporting period the medical device team helped 2 innovative
device products to be successfully listed (bronchial navigation operation control system and mitral valve clamp system) the
registration team helped 2 products to be registered and listed in China and approved 29 INDMRCT clinical trial applications
were granted with clinical approvals in multiple countries and 21 new US FDA IND projects were added of which 19 have been
accepted by the FDA and the numerical statistics department helped 11 new drugs were approved in China the United States
and Japan the site management team provided SMO site management services for 9 approved Class 1 new drugs in China the
independent image evaluation team successfully helped 3 new drugs to be approved for marketing and 4 projects to be
submitted for filing
泰格医药 (300347 CH)
Market share maintains leading position and outbound acquisitions strengthen global layout 2023 Tiger Pharma maintains the
leading position in Chinas clinical outsourcing service market with 128% market share and is the only Chinese clinical
represented by the United States Australia and Europe to establish independent overseas business capabilities and brands and
to expand local projects for foreign clients on the basis of stabilizing domestic clients overseas projects
Considering that the domestic biomedical investment and financing environment is still in the gradual recovery stage and the
growth rate of RD expenditure of biopharmaceutical enterprise customers is slowing downwe expect Tiger Pharmas 2024-
2026 revenues to be 7178 8388 9913 billion yuan respectively with year-on-year growth rates of -28% 169% 182% net
attributable profit to be 1297 2058 2298 billion yuan respectively with year-on-year growth rates of -359% 586% 117%
and non-deductible net attributable profit to be 1445 1758 1948 billion yuan year-on-year growth rate of -22% 217% 108%
share of 5846 yuan maintain the outperform rating
APPENDIX 2
Environmental
公司注重环境保护，减少碳排放
注重劳工健康和安全，无健康或者人口风险
Governance
公司无道德相关争议，公司薪酬合理
IMPORTANT DISCLOSURES
This research report is distributed by Haitong International a global brand name for the equity research teams of Haitong International Research Limited (HTIRL) Haitong Securities India Private
Limited (HSIPL) Haitong International Japan KK (HTIJKK) Haitong International Securities Company Limited (HTISCL) and any other members within the Haitong International Securities Group
of Companies (HTISG) each authorized to engage in securities activities in its respective jurisdiction
我， 孟科含，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表
whom I have already notified of this will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published
利益冲突披露Conflict of Interest Disclosures
海通国际及其某些关联公司可从事投资银行业务和或对本研究中的特定股票或公司进行做市或持有自营头寸。就本研究报告而言，以下是有关该等关系的披露事项（以下披露不能保
评级定义（从2020 年7 月1 日开始执行）：
海通国际（以下简称HTI）采用相对评级系统来为投资者推荐我们覆盖的公
司：优于大市、中性或弱于大市。投资者应仔细阅读HTI 的评级定义。并且HTI
基于各自情况（比如投资者的现有持仓）以及其他因素。
优于大市，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据
FINRANYSE 的评级分布规则，我们会将中性评级划入持有这一类别。
弱于大市，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 美
国  SP500 其他所有中国概念股  MSCI China
Ratings Definitions (from 1 Jul 2020)
Haitong International uses a relative rating system using Outperform
investors Investors should carefully read the definitions of all ratings used
in Haitong International Research In addition since Haitong International
views investors should carefully read Haitong International Research in its
entirety and not infer the contents from the rating alone In any case
ratings (or research) should not be used or relied upon as investment
advice An investors decision to buy or sell a stock should depend on
individual circumstances (such as the investors existing holdings) and other
considerations
Analyst Stock Ratings
Outperform The stocks total return over the next 12-18 months is
评级分布Rating Distribution
expected to exceed the return of its relevant broad market benchmark as
indicated below
Neutral The stocks total return over the next 12-18 months is expected to
be in line with the return of its relevant broad market benchmark as
indicated below For purposes only of FINRANYSE ratings distribution
rules our Neutral rating falls into a hold rating category
Underperform The stocks total return over the next 12-18 months is
expected to be below the return of its relevant broad market benchmark
as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX
Korea  KOSPI Taiwan  TAIEX India  Nifty100 US  SP500 for all other
China-concept stocks  MSCI China
截至2024 年6 月30 日海通国际股票研究评级分布
在每个评级类别里投资银行客户所占的百分比。
上述分布中的买入，中性和卖出分别对应我们当前优于大市，中性和落后大市评级。
只有根据FINRANYSE 的评级分布规则，我们才将中性评级划入持有这一类别。请注意在上表中不包含非评级的股票。
此前的评级系统定义（直至2020 年6 月30 日）：
买入，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如下
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据FINRANYSE 的评级分布规则，我们会将中性评级划入持有这一类别。
卖出，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如下
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 其他所有中国概念股  MSCI China
Haitong International Equity Research Ratings Distribution as of June 30 2024
HTI Equity Research Coverage
IB clients
Percentage of investment banking clients in each rating category
BUY Neutral and SELL in the above distribution correspond to our current ratings of Outperform Neutral and Underperform
For purposes only of FINRANYSE ratings distribution rules our Neutral rating falls into a hold rating category Please note that stocks with an NR designation are not included in the table above
Previous rating system definitions (until 30 Jun 2020)
BUY The stocks total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark as indicated below
NEUTRAL The stocks total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark as indicated below For purposes
only of FINRANYSE ratings distribution rules our Neutral rating falls into a hold rating category
SELL The stocks total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX Korea  KOSPI Taiwan  TAIEX India  Nifty100 for all other China-concept stocks  MSCI China
海通国际非评级研究：海通国际发布计量、筛选或短篇报告，并在报告中根据估值和其他指标对股票进行排名，或者基于可能的估值倍数提出建议价格。这种排名或建议价格并非为
了进行股票评级、提出目标价格或进行基本面估值，而仅供参考使用。
Haitong International Non-Rated Research  Haitong International publishes quantitative screening or short reports which may rank stocks according to valuation and other metrics or may suggest
prices based on possible valuation multiples Such rankings or suggested prices do not purport to be stock ratings or target prices or fundamental values and are for information only
Haitong International Coverage of A-Shares  Haitong International may cover and rate A-Shares that are subject to the Hong Kong Stock Connect scheme with Shanghai and Shenzhen Haitong
system employed by HS differs from that used by HTI and as a result there may be a difference in the HTI and HS ratings for the same A-share stocks
股团队自下而上的研究。海通国际每季对Q100 指数成分作出复审。
Haitong International Quality 100 A-share (Q100) Index  HTIs Q100 Index is a quant product that consists of 100 of the highest-quality A-shares under coverage at HS in Shanghai These stocks are
盟浪义利（FIN-ESG）数据通免责声明条款：在使用盟浪义利（FIN-ESG）数据之前，请务必仔细阅读本条款并同意本声明：
第一条 义利（FIN-ESG）数据系由盟浪可持续数字科技有限责任公司（以下简称本公司）基于合法取得的公开信息评估而成，本公司对信息的准确性及完整性不作任何保证。对公司
述的评估结果造成的任何直接或间接损失负责。
第二条 盟浪并不因收到此评估数据而将收件人视为客户，收件人使用此数据时应根据自身实际情况作出自我独立判断。本数据所载内容反映的是盟浪在最初发布本数据日期当日的判
断，盟浪有权在不发出通知的情况下更新、修订与发出其他与本数据所载内容不一致或有不同结论的数据。除非另行说明，本数据（如财务业绩数据等）仅代表过往表现，过往的业
绩表现不作为日后回报的预测。
第三条 本数据版权归本公司所有，本公司依法保留各项权利。未经本公司事先书面许可授权，任何个人或机构不得将本数据中的评估结果用于任何营利性目的，不得对本数据进行修
改、复制、编译、汇编、再次编辑、改编、删减、缩写、节选、发行、出租、展览、表演、放映、广播、信息网络传播、摄制、增加图标及说明等，否则因此给盟浪或其他第三方造
成损失的，由用户承担相应的赔偿责任，盟浪不承担责任。
第四条 如本免责声明未约定，而盟浪网站平台载明的其他协议内容（如盟浪网站用户注册协议盟浪网用户服务（含认证）协议盟浪网隐私政策等）有约定的，则按其他
协议的约定执行；若本免责声明与其他协议约定存在冲突或不一致的，则以本免责声明约定为准。
SusallWave FIN-ESG Data Service Disclaimer Please read these terms and conditions below carefully and confirm your agreement and acceptance with these terms before using SusallWave FIN-
ESG Data Service
FIN-ESG Data is produced by SusallWave Digital Technology Co Ltd (In short SusallWave)s assessment based on legal publicly accessible information SusallWave shall not be responsible
selling or holding any relative financial products We will not be liable for any direct or indirect loss of any individual or institution as a result of using SusallWave FIN-ESG Data
SusallWave do not consider recipients as customers for receiving these data When using the data recipients shall make your own independent judgment according to your practical individual
status The contents of the data reflect the judgment of us only on the release day We have right to update and amend the data and release other data that contains inconsistent contents or
different conclusions without notification Unless expressly stated the data (eg financial performance data) represents past performance only and the past performance cannot be viewed as the
prediction of future return
abbreviation excerpts issuance rent exhibition performance projection broadcast information network transmission shooting adding icons and instructions If any loss of SusallWave or any
If any term is not contained in this disclaimer but written in other agreements on our website (eg User Registration Protocol of SusallWave Website User Service (including authentication)
Agreement of SusallWave Website Privacy Policy of Susallwave Website) it should be executed according to other agreements If there is any difference between this disclaim and other agreements
this disclaimer shall be applied
行，包括制作及发布涵盖BSE Limited（BSE）和National Stock Exchange of India Limited（NSE）上市公司（统称为印度交易所）的研究报告。HTSIPL 于2016 年12 月22 日被收购
声明或保证。本文件中所有观点均截至本报告日期，如有更改，恕不另行通知。本文件仅供参考使用。文件中提及的任何公司或其股票的说明并非意图展示完整的内容，本文件并非
可能会对投资产生不利影响。过去的表现并不一定代表将来的结果。某些特定交易，包括设计金融衍生工具的，有产生重大风险的可能性，因此并不适合所有的投资者。您还应认识到
其他方面的专业顾问，以期在投资之前评估该项建议是否适合于您。若由于使用本文件所载的材料而产生任何直接或间接的损失，HTISG 及其董事、雇员或代理人对此均不承担任何责
HTISG 的销售员、交易员和其他专业人士均可向HTISG 的相关客户和公司提供与本文件所述意见相反的口头或书面市场评论意见或交易策略。HTISG 可做出与本文件所述建议或意见不
一致的投资决策。但HTIRL 没有义务来确保本文件的收件人了解到该等交易决定、思路或建议。
For research reports on non-Indian securities The research report is issued by Haitong International Research Limited (HTIRL) a wholly owned subsidiary of Haitong International Securities Group
Limited (HTISGL) and a licensed corporation to carry on Type 4 regulated activity (advising on securities) for the purpose of the Securities and Futures Ordinance (Cap 571) of Hong Kong with the
assistance of Haitong International (Japan) KK (HTIJKK) a wholly owned subsidiary of HTISGL and which is regulated as an Investment Adviser by the Kanto Finance Bureau of Japan
registered Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research reports covering listed entities on the BSE Limited (BSE) and the National Stock
Exchange of India Limited (NSE) (collectively referred to as Indian Exchanges) HSIPL was acquired and became part of the Haitong International Securities Group of Companies (HTISG) on 22
December 2016
All the research reports are globally branded under the name Haitong International and approved for distribution by Haitong International Securities Company Limited (HTISCL) andor any other
members within HTISG in their respective jurisdictions
referred to in this research report may not be eligible for purchase or sale in some jurisdictions If an investment product is denominated in a currency other than an investors home currency a
change in exchange rates may adversely affect the investment Past performance is not necessarily indicative of future results Certain transactions including those involving derivatives give rise to
your unique financial circumstances such as your financial situation and risk appetite You must therefore analyze and should where applicable consult your own legal tax accounting financial
for any direct or consequential loss arising from any use of the materials contained in this research report
HTISG and our affiliates officers directors and employees excluding the analysts responsible for the content of this document will from time to time have long or short positions in act as principal
to the attention of any recipient of this research report
with respect to Research
Non US Analyst Disclosure  The HTI analyst(s) listed on the cover of this Research is (are) not registered or qualified as a  research analyst with FINRA and are not subject to US FINRA Rule 2241
期货事务监察委员会的审查。您不应仅根据本研究报告中所载的信息做出投资决定。本研究报告的收件人就研究报告中产生或与之相关的任何事宜请联系HTISCL 销售人员。
美国投资者的通知事项：本研究报告由HTIRL，HSIPL 或HTIJKK 编写。 HTIRL，HSIPL，HTIJKK 以及任何非HTISG 美国联营公司，均未在美国注册，因此不受美国关于研究报告编制和研
资者（US Institutional Investors）。在向美国机构投资者分发研究报告时，Haitong International Securities (USA) Inc （HTI USA） 将对报告的内容负责。任何收到本研究报告的美国
351-6050。 HTI USA 是在美国于US Securities and Exchange Commission（SEC）注册的经纪商，也是Financial Industry Regulatory Authority Inc（FINRA）的成员。 HTIUSA 不负责编写
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
DISTRIBUTION AND REGIONAL NOTICES
Except as otherwise indicated below any Recipient wishing to discuss this research report or effect any transaction in any security discussed in HTIs research should contact the Haitong International
salesperson in their own country or region
Notice to Hong Kong investors The research report is distributed by Haitong International Securities Company Limited (HTISCL) which is a licensed corporation to carry on Type 1 regulated activity
(dealing in securities) in Hong Kong This research report does not constitute a solicitation or an offer of securities or an invitation to the public within the meaning of the SFO This research report
is only to be circulated to Professional Investors as defined in the SFO This research report has not been reviewed by the Securities and Futures Commission You should not make investment
decisions solely on the basis of the information contained in this research report Recipients of this research report are to contact HTISCL salespersons in respect of any matters arising from or in
connection with the research report
Notice to US investors As described above this research report was prepared by HTIRL HSIPL or HTIJKK Neither HTIRL HSIPL HTIJKK nor any of the non US HTISG affiliates is registered in the
United States and therefore is not subject to US rules regarding the preparation of research reports and the independence of research analysts  This research report is provided for distribution to
major US institutional investors and US institutional investors in reliance on the exemption from registration provided by Rule 15a-6 of the US Securities Exchange Act of 1934 as amended
When distributing research reports to US institutional investors HTI USA will accept the responsibilities for the content of the reports  Any US recipient of this research report wishing to effect
any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Haitong International Securities (USA)
Inc (HTI USA) located at 340 Madison Avenue 12th Floor New York NY 10173 USA telephone (212) 351 6050  HTI USA is a broker-dealer registered in the US with the US Securities and
Exchange Commission (the SEC) and a member of the Financial Industry Regulatory Authority Inc (FINRA)  HTI USA is not responsible for the preparation of this research report nor for the
analysis contained therein  Under no circumstances should any US recipient of this research report contact the analyst directly or effect any transaction to buy or sell securities or related financial
instruments directly through HSIPL HTIRL or HTIJKK  The HSIPL HTIRL or HTIJKK analyst(s) whose name appears in this research report is not registered or qualified as a research analyst with FINRA
in any non-US securities or related financial instruments (including ADRs) discussed in this research report may present certain risks  The securities of non-US issuers may not be registered with
financial instruments All inquiries by US recipients should be directed to
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
Attn  Sales Desk at (212) 351 6050
中华人民共和国的通知事项：在中华人民共和国（下称中国，就本报告目的而言，不包括香港特别行政区、澳门特别行政区和台湾）只有根据适用的中国法律法规而收到该材料的人
103 Registration Requirements Exemptions and Ongoing Registrant Obligations（NI 31-103）的规定得到国际交易商豁免（International Dealer Exemption ）的交易商，位于艾伯塔
National Instrument 45-106 Prospectus Exemptions 第11 节或者Securities Act (Ontario)第733(1)节所规定的认可投资者（Accredited Investor），或者在适用情况下National
Instrument 31-103 第11 节所规定的许可投资者（Permitted Investor）。
新加坡投资者的通知事项：本研究报告由Haitong International Securities (Singapore) Pte Ltd（HTISSPL）于新加坡提供。HTISSPL 是符合财务顾问法2001（FAA）定义的豁免财务
HTISSPL 联系：
Haitong International Securities (Singapore) Pte Ltd
10 Collyer Quay 19-01 - 19-05 Ocean Financial Centre Singapore 049315
（1）条，第17-11（1）条的执行及相关条款）。
相关的投资行为只面对此类专业客户。没有投资经验或相关投资经验的客户不得依赖本报告。Haitong International Securities Company Limited 的分支机构的净长期或短期金融权益可能
超过本研究报告中提及的实体已发行股本总额的05。特别提醒有些英文报告有可能此前已经通过中文或其它语言完成发布。
澳大利亚投资者的通知事项：Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Company Limited 和Haitong International Securities (UK) Limited 分别根据澳
等法律与在澳大利亚所适用的法律存在差异。
发布，包括制作及发布涵盖BSE Limited（BSE）和National Stock Exchange of India Limited（NSE）（统称为印度交易所）研究报告。
研究机构名称 Haitong Securities India Private Limited
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
请注意，SEBI 授予的注册和 NISM 的认证并不保证中介的表现或为投资者提供任何回报保证。
本项研究仅供收件人使用，未经海通国际的书面同意不得予以复制和再次分发。
Peoples Republic of China (PRC) In the PRC the research report is directed for the sole use of those who receive the research report in accordance with the applicable PRC laws and regulations
Further the information on the research report does not constitute production and business activities in the PRC under relevant PRC laws This research report does not constitute a public offer
of the security whether by sale or subscription in the PRC Further no legal or natural persons of the PRC may directly or indirectly purchase any of the security or any beneficial interest therein
these restrictions
Notice to Canadian Investors Under no circumstances is this research report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada
Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and
only by Haitong International Securities (USA) Inc a dealer relying on the international dealer exemption under National Instrument 31-103 Registration Requirements Exemptions and Ongoing
Registrant Obligations (NI 31-103) in Alberta British Columbia Ontario and Quebec This research report is not and under no circumstances should be construed as a prospectus an offering
research report the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence Upon receipt of this research report each
Canadian recipient will be deemed to have represented that the investor is an accredited investor as such term is defined in section 11 of National Instrument 45-106 Prospectus Exemptions or
in Ontario in section 733(1) of the Securities Act (Ontario) as applicable and a permitted client as such term is defined in section 11 of NI 31-103 respectively
Notice to Singapore investors This research report is provided in Singapore by or through Haitong International Securities (Singapore) Pte Ltd (HTISSPL) HTISSPL is an Exempt Financial Adviser
under the Financial Advisers Act 2001 (FAA) to (a) advise on securities units in a collective investment scheme exchange-traded derivatives contracts and over-the-counter derivatives contracts
and (b) issue or promulgate research analyses or research reports on securities exchange-traded derivatives contracts and over-the-counter derivatives contracts This research report is only provided
to institutional investors within the meaning of Section 4A of the Securities and Futures Act 2001 Recipients of this research report are to contact HTISSPL via the details below in respect of any
matters arising from or in connection with the research report
Haitong International Securities (Singapore) Pte Ltd
10 Collyer Quay 19-01 - 19-05 Ocean Financial Centre Singapore 049315
Telephone (65) 6713 0473
Notice to Japanese investors This research report is distributed by Haitong International Securities Company Limited and intended to be distributed to Financial Services Providers or Registered
Financial Institutions engaged in investment management (as defined in the Japan Financial Instruments and Exchange Act (FIEL) Art 61(1) Order for Enforcement of FIEL Art 17-11(1) and related
articles)
Notice to UK and European Union investors This research report is distributed by Haitong International Securities Company Limited This research is directed at persons having professional
experience in matters relating to investments Any investment or investment activity to which this research relates is available only to such persons or will be engaged in only with such persons
Persons who do not have professional experience in matters relating to investments should not rely on this research  Haitong International Securities Company Limiteds affiliates may have a net
long or short financial interest in excess of 05% of the total issued share capital of the entities mentioned in this research report  Please be aware that any report in English may have been published
previously in Chinese or another language
Notice to Australian investors The research report is distributed in Australia by Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Company Limited and Haitong
International Securities (UK) Limited in reliance on ASIC Corporations (Repeal and Transitional) Instrument 2016396 which exempts those HTISG entities from the requirement to hold an Australian
financial services license under the Corporations Act 2001 in respect of the financial services it provides to wholesale clients in Australia  A copy of the ASIC Class Orders may be obtained at the
International Securities (UK) Limited are regulated under foreign laws and regulatory requirements which are different from the laws applying in Australia
Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research reports covering listed entities on the BSE Limited (BSE) and the National Stock Exchange of
India Limited (NSE) (collectively referred to as Indian Exchanges)
Name of the entity Haitong Securities India Private Limited
SEBI Research Analyst Registration Number INH000002590
Address  1203A Floor 12A Tower 2A One World Center
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
Please note that Registration granted by SEBI and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors
This research report is intended for the recipients only and may not be reproduced or redistributed without the written consent of an authorized signatory of HTISG
Copyright Haitong International Securities Group Limited 2019 All rights reserved
Source Company data Bloomberg HTI estimates